Streetbeat News

Analyst Ratings

CRIS

The FDA has removed the partial clinical hold on Curis Inc's TakeAim Leukemia Phase 1/2 study of emavusertib for hematologic malignancies. The recommended phase 2 dose for emavusertib has been established. HC Wainwright maintains its Buy rating for Curis but lowers the price target to $6 from $9 due to delayed launch expectations for AML/MDS and the dilution associated with the recent capital raise. The analyst forecasts a launch for emavusertib for AML/MDS in late 2027, with sales of $23.3 million that year, growing to $452 million in 2029.

Portfolio Pulse from Vandana Singh

July 07, 2023 | 5:28 pm

BIIB

ESALY

The FDA has approved a supplemental marketing application for Biogen Inc (NASDAQ:BIIB) and Eisai Co Ltd's (OTC:ESALY) Leqembi, the first approved treatment shown to reduce the rate of disease progression in adults with Alzheimer's disease. Concurrently, CMS confirmed broader Medicare coverage for Leqembi. Analysts from William Blair, Raymond James, Oppenheimer, and Needham provided their perspectives on the development, with a general consensus that the approval and expanded coverage may not significantly change the outlook for Leqembi.

Portfolio Pulse from Vandana Singh

July 07, 2023 | 5:25 pm

APLD

Needham & Co. analyst John Todaro has raised the price target for Applied Digital Corp (NASDAQ:APLD) to $16.00 from $8.50, maintaining a Buy rating. The analyst sees APLD's downside as limited due to its stable Bitcoin mining segment, which is expected to remain strong until mid-2024. The FY24 revenue estimate has been raised to $309.4 million due to a strong demand pipeline, as evidenced by new AI contracts. APLD shares are currently trading higher by 5.10% at $8.09.

Portfolio Pulse from Lekha Gupta

July 07, 2023 | 5:24 pm

ALPMY

GSK

MRK

PFE

Goldman Sachs research suggests the global pharmaceutical sector has approximately $700 billion available for M&A and investments. This comes as patents for some blockbuster drugs are nearing expiration. Recent examples include Astellas Pharma acquiring Iveric Bio, Pfizer proposing to acquire Seagen, GSK agreeing to acquire BELLUS Health, and Merck announcing to acquire Prometheus Biosciences. The healthcare sector had a challenging start to 2023 due to regulatory & growth concerns, macroeconomic rotations, and investor preference for large-cap technology stocks.

Portfolio Pulse from Vandana Singh

July 07, 2023 | 5:18 pm

NYCB

Over the past 3 months, 4 analysts have published their opinion on New York Community (NYSE:NYCB) stock. The average price target for NYCB is $12.0, with a high of $14.00 and a low of $11.00. This average price target has increased by 5.91% over the past month.

Portfolio Pulse from Benzinga Insights

July 07, 2023 | 5:02 pm

SIX

Six Flags Entertainment (NYSE:SIX) has received mixed analyst ratings in the last quarter, with 2 bullish, 2 somewhat bullish, 6 indifferent, and 1 bearish. The average 12-month price target for the company has increased by 4.07% from $29.00 to $30.18, according to 11 analysts. Analysts typically base their ratings on the company's predicted earnings and revenue streams over the next five years.

Portfolio Pulse from Benzinga Insights

July 07, 2023 | 5:02 pm

ODFL

Raymond James has maintained its Outperform rating for Old Dominion Freight Line (NASDAQ:ODFL) and increased its price target from $350.00 to $385.00. ODFL's shares are currently trading up 3.29% at $378.11 per share. A move to $385.00 would represent a 1.82% increase from the current share price.

Portfolio Pulse from Benzinga Insights

July 07, 2023 | 5:01 pm

AEE

In the last quarter, Ameren (NYSE:AEE) received 1 bullish, 4 somewhat bullish, and 6 indifferent ratings from analysts. The average 12-month price target for Ameren is $91.64, a 1.67% decrease from the previous average of $93.20. Analyst ratings are derived from various sources including company conference calls, financial statements, and insider conversations.

Portfolio Pulse from Benzinga Insights

July 07, 2023 | 5:01 pm

PFG

Piper Sandler has maintained its Neutral rating for Principal Financial Group (NASDAQ:PFG) and raised its price target from $75.00 to $82.00. The shares of PFG are trading up 2.78% over the last 24 hours, at $77.29 per share. A move to $82.00 would account for a 6.09% increase from the current share price.

Portfolio Pulse from Benzinga Insights

July 07, 2023 | 5:01 pm

NWN

Guggenheim has maintained its Neutral rating for Northwest Natural Hldg (NYSE:NWN) but lowered its price target from $45.00 to $42.00. NWN's shares are currently trading down 0.38% at $42.17 per share. A move to $42.00 would represent a 0.4% decrease from the current share price.

Portfolio Pulse from Benzinga Insights

July 07, 2023 | 5:01 pm